COMPLETEDPHASE2/PHASE3

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

NCT02174432•Trevi Therapeutics

View on ClinicalTrials.gov

Summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subject completed participation in the TR03 study

Exclusion Criteria

•Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study.
•Subject is a pregnant or lactating female

Locations (1)

University of Münster

Münster, Germany

Key Dates

Start Date

August 15, 2015

Primary Completion Date

September 3, 2017

Completion Date

September 3, 2017

Last Updated

May 21, 2025

Enrollment

36

ACTUAL participants

Conditions

Prurigo NodularisNodularis PrurigoPrurigo

Interventions

nalbuphine HCl ER

DRUG

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952

Prurigo Nodularis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE3